Rejuversen (formerly Rejuveron Senescence Therapeutics) is a biotech company developing novel medicines that target senescence in age-related diseases associated with fibrosis and in oncology
View Top Employees from Rejuveron Senescence Therapeutics| Website | http://www.rejuveron.com |
| Employees | 26 (26 on RocketReach) |
| Founded | 2020 |
| Address | 5 Grafenaustrasse, Zug, Zug 6300, CH |
| Industry | Biotechnology Research, Business Services General, Drug Discovery, Business Services, Biotechnology |
| SIC | SIC Code 283 Companies, SIC Code 80 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Rejuveron Senescence Therapeutics employee's phone or email?
Rejuveron Senescence Therapeutics Questions
Matthias Steger is the CEO of Rejuveron Senescence Therapeutics.
26 people are employed at Rejuveron Senescence Therapeutics.
Rejuveron Senescence Therapeutics is based in Zug, Zug.
The NAICS codes for Rejuveron Senescence Therapeutics are [325, 32, 3254].
The SIC codes for Rejuveron Senescence Therapeutics are [283, 80, 28].
Top Rejuveron Senescence Therapeutics Employees
-
ViewMatthias Steger
Chief Executive Officer at Rejuveron Senescence Therapeutics
Zurich, Zurich, Switzerland33 -
1
-
ViewIan Metcalfe
Vice President Venture Development at Rejuveron Senescence Therapeutics
Basel, Basel-Stadt, Switzerland1 -
2
-
ViewAksana Labokha
Chief Executive Officer at Rejuveron Senescence Therapeutics
Edinburgh, Edinburgh, United Kingdom4
Related Companies
